Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma
Ivana N. Micallef, Patrick J. Stiff, Edward A. Stadtmauer, Brian J. Bolwell, Auayporn P. Nademanee, Richard T. Maziarz, Angela M. Partisano, Sachin Marulkar, John F. Dipersio
Dive into the research topics of 'Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma'. Together they form a unique fingerprint.